D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer

Cancer Research

Volumn 73, Issue 23, 2013, Pages 6856-6864

  Merenbakh Lamin, Keren ^a,b   Ben Baruch, Noa ^d   Yeheskel, Adva ^b   Dvir, Addie ^e   Soussan Gutman, Lior ^e   Jeselsohn, Rinath ^f,h   Yelensky, Roman ^g   Brown, Myles ^f,h   Miller, Vincent A ^g   Sarid, David ^a   Rizel, Shulamith ^e   Klein, Baruch ^c   Rubinek, Tami ^a   Wolf, Ido ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ASSUTA MEDICAL CENTER   (Israel)

^d KAPLAN MEDICAL CENTER   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g FOUNDATION MEDICINE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ESTROGEN RECEPTOR ALPHA; GLYCINE; NUCLEAR RECEPTOR COACTIVATOR 2; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN;

AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL MIGRATION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; ER ALPHA GENE; GENE MUTATION; GENETIC ANALYSIS; HORMONE ACTION; HUMAN; HUMAN TISSUE; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84890252506     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1197     Document Type: Article

References (28)

1. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 2006;27:299-402.
2. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47.
3. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98.
4. Giulino-Roth L, Wang K, MacDonald TY, et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012;120:5181-4.
5. Wolf I, Levanon-Cohen S, Bose S, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008;27:7094-105.
6. Liang C, Park A, Guan J. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2:329-33.
7. Koide A, Abbatiello S, Rothgery L, Koide S. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci U S A 2002;99:1253-8.
8. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
9. Jaroszewski L, Li Z, Cai XH, Weber C, Godzik A. FFAS server: novel features and applications. Nucleic Acids Res 2011;39:W38-44.
10. Misura KM, Baker D. Progress and challenges in high-resolution refinement of protein structure models. Proteins 2005;59:15-29.
11. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39:W270-7.
12. Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Bio Chem 2003;278:7630-8.
13. Zhong L, Skafar DF. Mutations of tyrosine 537 in the human estrogen receptor-alpha selectively alter the receptor's af finity for estradiol and the kinetics of the interaction. Biochemistry 2002;41:4209-17.
14. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-6.
15. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010;16:2702-8.
16. Fuqua SA, Wiltschke C, Zhang QX, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000;60:4026-9.
17. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1244-9.
18. Reid G, Denger S, Kos M, Gannon F. Human estrogen receptor-alpha: regulation by synthesis, modifi cation and degradation. Cell Mol Life Sci 2002;59:821-31.
19. Wolf D, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994;31:129-38.
20. Liu H, Lee ES, Deb Los Reyes A, Zapf JW, Jordan VC. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 2001;61:3632-9.
21. MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000;60:5097-105.
22. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
23. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour pro filed at single nucleotide resolution. Nature 2009;461:809-13.
24. Lorusso G, Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012;22:226-33.
25. Koo JS, Jung W, Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010;96:424-32.
26. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004;10:2336-43.
27. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002;87:1354-9.
28. Estevez L, Alvarez I, Tusquets I, et al. Finding the right dose of fulvestrant in breast cancer. Cancer Treat Rev 2013;39:136-41.